{"SPADE_UN_17043": {"Clinical Information": [], "Patent Information": [], "Sequence Information": {"SPADE ID": "SPADE_UN_17043", "Peptide Name": "E-selectin-binding peptide", "Source": "Synthetic", "Family": "", "Gene": "Not found", "Sequence": "CDSDSDITWDQLWDLMK", "Sequence Length": 17, "UniProt Entry": ["http://www.uniprot.org/uniprot/Notavailable"], "Protein Existence": "Not found", "Biological Activity": ["Antimicrobial", "Anticancer"], "Target Organism": "Not available", "Hemolytic Activity": "Not available", "Cytotoxicity": "Not available", "Binding Target": "Not available", "Linear/Cyclic": "", "N-terminal Modification": "Free", "C-terminal Modification": "Free", "Stereochemistry": "L", "Structure Description": "Not found", "Formula": "C89H131N21O32S2", "Mass": 2071.24, "PI": 4.05, "Net Charge": -4, "Hydrophobicity": -0.74, "Half Life": "Mammalian:1.2 hourYeast:>20 hourE.coli:>10 hour", "Literature": [{"Title": "How molecular imaging is speeding up antiangiogenic drug development", "Pubmed ID": "17121909", "Reference": "Mol Cancer Ther. 2006 Nov;5(11)2624-33.", "Author": "Cai W, Rao J, Gambhir SS, Chen X.", "URL": "http://www.ncbi.nlm.nih.gov/pubmed/?term=17121909"}], "Frequent Amino Acids": "DLS", "Absent Amino Acids": "AEFGHNOPRUVY", "Basic Residues": 1, "Acidic Residues": 5, "Hydrophobic Residues": 6, "Polar Residues": 6, "Positive Residues": 1, "Negative Residues": 5, "Similar Sequences": [{"SPADE_ID": "SPADE_N_00224", "Similarity": 0.5714285714285714, "Sequence": "EALYNSEDLYEETSDSDD"}, {"SPADE_ID": "SPADE_N_05107", "Similarity": 0.5, "Sequence": "LDVPHVYLRDTKDCSKITIGNLPTEPFEVTVSAYREPSDITVGMIPVSFIEGDFDKYYEDFASDITKRLKDMAKLKEDSHKQAVDSINKEKVAEVVMFFE"}]}}}